Compare Illumina, Inc. (ILMN) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Wynn Resorts, Limited — how do they compare? Illumina, Inc. trades at $190.45 (market cap $27.94B), while Wynn Resorts, Limited trades at $95.24 (market cap $9.93B). The key difference: Illumina, Inc. is far larger — about 2.8× Wynn Resorts, Limited's market cap, and Wynn Resorts, Limited pays a 1.05% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | WYNN | |
|---|---|---|
Market Cap | $27.94B | $9.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $133.34 |
52-Week Low | $91.00 | $94.78 |
Enterprise Value | $29.33B | $20.29B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Wynn Resorts (WYNN) trades at $95.61, down 1.07% today, with a bearish technical signal and mixed earnings history including three consecutive quarterly misses. The company maintains strong revenue growth from $3.8B in 2022 to $7.1B in 2025, though net margins have compressed from 11.17% to 4.58% over the same period. Recent news highlights Q1 2026 earnings beating estimates with $1.25 EPS (Zacks Investment Research, May 7, 2026), while long-term debt remains elevated at $10.50B.
Analyst consensus is bullish with a $135.50 price target (64% buy ratings), but risks include high leverage, margin pressure from Macau competition, and geopolitical challenges for the UAE expansion. The stock offers 42% upside to consensus target if operational execution improves, though investors face volatility from earnings inconsistency and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
